Bio-Rad Laboratories, Inc. (BIO) Debt to Assets Ratio: 0.14%
The debt to assets ratio for Bio-Rad Laboratories, Inc. (BIO) is 0.14% as of Tuesday, June 9, 2026.
BIO Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.14%
BIO Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | — | 0.14% |
| Charles River Laboratories International, Inc. (CRL) | $9.14B | 0.43% |
| Hims & Hers Health, Inc. (HIMS) | $6.46B | 0.59% |
| Align Technology, Inc. (ALGN) | $12.76B | 0.02% |
| Hologic, Inc. (HOLX) | $16.97B | 0.29% |
| Moderna, Inc. (MRNA) | $18.94B | 0.16% |
| BioNTech SE (BNTX) | $21.87B | 0.01% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 0.63% |
| Waters Corporation (WAT) | $24.19B | 0.29% |
| Veeva Systems Inc. (VEEV) | $27.37B | 0.01% |
Leverage Ratios Comparison
Debt/Assets
0.1%
Debt/Equity
0.21
Current Ratio
5.62
Interest Coverage
5.5x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Bio-Rad Laboratories, Inc. Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The debt to assets ratio for BIO stock is 0.14%.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz